EXACT Therapeutics AS (OSL: EXTX)

Market Cap	114.85M
Revenue (ttm)	n/a
Net Income (ttm)	-54.84M
Shares Out	32.08M
EPS (ttm)	-1.66
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	97,911
Average Volume	41,891
Open	3.800
Previous Close	3.460
Day's Range	3.300 - 3.800
52-Week Range	3.140 - 12.000
Beta	0.21
RSI	39.98
Earnings Date	Jan 3, 2025

About EXACT Therapeutics AS

EXACT Therapeutics AS, a clinical stage biopharmaceutical company, develops a technology platform for targeted therapeutic enhancement, Acoustic Cluster Therapy (ACT). The ACT is an approach to ultrasound-mediated, targeted drug enhancement with the potential to amplify the clinical utility of a range of therapeutic agents across various indications, including within oncology and brain diseases. The company’s ACT platform is under Phase I clinical trial for treatment of liver metastases; and pre-clinical studies for pancreatic, glioblastoma, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Employees: 12
• Stock Exchange: Oslo Børs
• Ticker Symbol: EXTX

Financial Performance

In 2023, EXACT Therapeutics AS's revenue was 4,458, a decrease of -99.02% compared to the previous year's 454,515. Losses were -48.33 million, 20.5% more than in 2022.